Contemporary in-hospital and long-term prognosis of patients with acute ST-elevation myocardial infarction depending on renal function: a retrospective analysis.
Humans
ST Elevation Myocardial Infarction
/ diagnosis
Retrospective Studies
Prognosis
Renal Insufficiency, Chronic
/ diagnosis
Anterior Wall Myocardial Infarction
/ complications
Arrhythmias, Cardiac
/ complications
Hospitals
Kidney
/ physiology
Hospital Mortality
Risk Factors
Treatment Outcome
Percutaneous Coronary Intervention
/ adverse effects
30-day mortality
Acute myocardial infarction
Chronic kidney disease
Overall survival
Real world data
Journal
BMC cardiovascular disorders
ISSN: 1471-2261
Titre abrégé: BMC Cardiovasc Disord
Pays: England
ID NLM: 100968539
Informations de publication
Date de publication:
02 02 2023
02 02 2023
Historique:
received:
22
11
2021
accepted:
19
01
2023
entrez:
2
2
2023
pubmed:
3
2
2023
medline:
7
2
2023
Statut:
epublish
Résumé
Cardiovascular disease is often associated with chronic kidney disease (CKD), resulting in an increased risk for poor outcome. We sought to determine short-term mortality and overall survival in ST-elevation myocardial infarction (STEMI) patients with different stages of CKD. In our retrospective cohort study with health insurance claims data of the Allgemeine Ortskrankenkasse (AOK), anonymized data of all STEMI patients hospitalized between 2010 and 2017 were analyzed regarding presence and severity of concomitant CKD. A total of 175,187 patients had an index-hospitalisation for STEMI (without CKD: 78.6% patients, CKD stage 1: 0.8%, CKD stage 2: 4.8%, CKD stage 3: 11.7%, CKD stage 4: 2.8%, CKD stage 5: 0.7%, CKD stage 5d: 0.6%). Patients with CKD were older and had more co-morbidities than patients without CKD. With increasing CKD severity, patients received less revascularization therapies (91.2%, 85.9%, 87.0%, 81.8%, 71.7%, 76.9% and 78.6% respectively, p < 0.001). After 1 year, guideline-recommended medications were prescribed less frequently in advanced CKD (83.4%, 79.3%, 81.5%, 74.7%, 65.0%, 59.4% and 53.7%, respectively, p < 0.001). CKD stages 4, 5 and 5d as well as chronic limb threatening ischemia (CLTI) were associated with decreased overall survival [CKD stage 4: hazard ratio (HR) 1.72; 95% CI 1.66-1.78; CKD stage 5: HR 2.55; 95% CI 2.37-2.73; CKD stage 5d: 5.64; 95% CI 5.42-5.86; CLTI: 2.06; 95% CI 1.98-2.13; all p < 0.001]. CKD is a frequent co-morbidity in patients with STEMI and is associated with a worse prognosis especially in advanced stages. Guideline-recommended therapies in patients with STEMI and CKD are still underused.
Sections du résumé
BACKGROUND
Cardiovascular disease is often associated with chronic kidney disease (CKD), resulting in an increased risk for poor outcome. We sought to determine short-term mortality and overall survival in ST-elevation myocardial infarction (STEMI) patients with different stages of CKD.
METHODS
In our retrospective cohort study with health insurance claims data of the Allgemeine Ortskrankenkasse (AOK), anonymized data of all STEMI patients hospitalized between 2010 and 2017 were analyzed regarding presence and severity of concomitant CKD.
RESULTS
A total of 175,187 patients had an index-hospitalisation for STEMI (without CKD: 78.6% patients, CKD stage 1: 0.8%, CKD stage 2: 4.8%, CKD stage 3: 11.7%, CKD stage 4: 2.8%, CKD stage 5: 0.7%, CKD stage 5d: 0.6%). Patients with CKD were older and had more co-morbidities than patients without CKD. With increasing CKD severity, patients received less revascularization therapies (91.2%, 85.9%, 87.0%, 81.8%, 71.7%, 76.9% and 78.6% respectively, p < 0.001). After 1 year, guideline-recommended medications were prescribed less frequently in advanced CKD (83.4%, 79.3%, 81.5%, 74.7%, 65.0%, 59.4% and 53.7%, respectively, p < 0.001). CKD stages 4, 5 and 5d as well as chronic limb threatening ischemia (CLTI) were associated with decreased overall survival [CKD stage 4: hazard ratio (HR) 1.72; 95% CI 1.66-1.78; CKD stage 5: HR 2.55; 95% CI 2.37-2.73; CKD stage 5d: 5.64; 95% CI 5.42-5.86; CLTI: 2.06; 95% CI 1.98-2.13; all p < 0.001].
CONCLUSIONS
CKD is a frequent co-morbidity in patients with STEMI and is associated with a worse prognosis especially in advanced stages. Guideline-recommended therapies in patients with STEMI and CKD are still underused.
Identifiants
pubmed: 36732721
doi: 10.1186/s12872-023-03084-3
pii: 10.1186/s12872-023-03084-3
pmc: PMC9896822
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
62Subventions
Organisme : Gemeinsamer Bundesausschuss
ID : 01VSF18051
Informations de copyright
© 2023. The Author(s).
Références
Eur Heart J. 2018 Jan 7;39(2):119-177
pubmed: 28886621
N Engl J Med. 2020 Apr 23;382(17):1608-1618
pubmed: 32227756
Hypertension. 2003 Nov;42(5):1050-65
pubmed: 14604997
J Am Coll Cardiol. 2019 Oct 8;74(14):1823-1838
pubmed: 31582143
J Am Heart Assoc. 2018 Aug 21;7(16):e009724
pubmed: 30369325
Heart. 2003 Sep;89(9):1003-8
pubmed: 12923009
BMC Cardiovasc Disord. 2018 Sep 24;18(1):184
pubmed: 30249197
BMC Nephrol. 2013 Mar 18;14:62
pubmed: 23506004
Curr Atheroscler Rep. 2019 Jun 22;21(9):32
pubmed: 31230129
Lancet. 2018 Nov 10;392(10159):1736-1788
pubmed: 30496103
Eur Heart J Acute Cardiovasc Care. 2020 May 06;:
pubmed: 33609123
BMC Fam Pract. 2019 Sep 14;20(1):132
pubmed: 31521114
PLoS One. 2016 Feb 09;11(2):e0148057
pubmed: 26859890
Circulation. 2013 Jan 29;127(4):e362-425
pubmed: 23247304
J Am Coll Cardiol. 2003 Mar 5;41(5):725-8
pubmed: 12628713
Ann Intern Med. 2002 Oct 1;137(7):555-62
pubmed: 12353942
Am J Kidney Dis. 2009 Nov;54(5):830-9
pubmed: 19592145
J Intern Med. 2010 Jul;268(1):40-9
pubmed: 20210836
Ren Fail. 2020 Nov;42(1):881-889
pubmed: 32862755
Aging (Albany NY). 2020 May 20;12(11):10863-10872
pubmed: 32433039
Am J Cardiol. 2015 Dec 15;116(12):1802-9
pubmed: 26602071
Clin Res Cardiol. 2021 Oct;110(10):1625-1636
pubmed: 34036426
J Am Heart Assoc. 2018 Dec 18;7(24):e010394
pubmed: 30514137
Circ Cardiovasc Qual Outcomes. 2022 Oct;15(10):e008995
pubmed: 36193750
BMC Cardiovasc Disord. 2014 Feb 07;14:15
pubmed: 24506974
Eur Heart J. 2015 Apr 14;36(15):932-8
pubmed: 25650396
Angiology. 2016 Jul;67(6):556-64
pubmed: 26324203
Am J Cardiol. 2012 Jan 1;109(1):19-25
pubmed: 21974963
Circ Cardiovasc Qual Outcomes. 2019 Sep;12(9):e005879
pubmed: 31510770
BMJ Open. 2015 Jun 23;5(6):e008188
pubmed: 26105033
Clin J Am Soc Nephrol. 2016 Feb 5;11(2):216-22
pubmed: 26668023
Kidney Int. 2011 Dec;80(12):1306-14
pubmed: 21849971
Clin Res Cardiol. 2020 Sep;109(9):1186-1192
pubmed: 32034482